Researchers Develop a Novel AI Algorithm for Digital Pathology Analysis
Researchers developed a novel AI algorithm to classify lung cancer subtype based on lung tissue images from resected tumors.
Researchers developed a novel AI algorithm to classify lung cancer subtype based on lung tissue images from resected tumors.
A recent report showed less than half of community oncologists used biomarker testing for lung cancer — compared to 73% of academic clinicians.
The test validation trial resulted in CyPath Lung specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer.
Israeli laboratories are approved to use molecular profiling assays for NSCLC patients using Thermo Fisher Scientific’s Oncomine Comprehensive Assay Plus.
Read MoreThe collaborators are pursuing regulatory approval of the Guardant360 CDx as a companion diagnostic for amivantamab for the treatment of NSCLC.
Read MoreInVisionFirst-Lung is a ctDNA next-generation sequencing liquid biopsy assay testing 37 genes relevant to the care of advanced NSCLC patients.
Read MoreArcherDx plans to leverage the personalized cancer monitoring assays to develop companion diagnostics for AstraZeneca’s associated immunooncology therapies.
Read MoreThe blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read MoreThe Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read MoreA noninvasive urine test that can detect the presence of proteins linked to lung cancer could help detect more tumors in the early stages of the disease.
Read MoreBluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
Read MoreTargeted cancer treatment using an ALK inhibitor in combination with a PIM1 inhibitor can increase the chances of survival of children with an unfavorable prognosis.
Read MoreT2 Biosystems has announced the appointment of diagnostics industry veteran John Sperzel as president and chief executive officer, succeeding John McDonough, who will continue with his board leadership role, serving as nonexecutive chairman.
Read MoreCaris Life Sciences’ Molecular Intelligence GPS score aids in the characterization of cancer of unknown primary and atypical cases, while also identifying appropriate treatment options.
Read MoreInnovative device enhances ease of use and reduces the costs and environmental impact of blood sample collection, processing, and shipping.
Read MoreThe Early Detection for Cancer of the Lung Scotland trial is believed to be the world’s largest trial for the detection of lung cancer using biomarkers.
Read MoreThe new genomic test is Veracyte’s first commercial product since the company signed a strategic collaboration with Johnson & Johnson Innovation.
Read MoreMultigene panels would deliver greater value if patients with actionable genetic mutations consistently received guided treatments.
Read More